Ubrogepant

Ubrogepant (MK-1602) is an orally active and selective antagonist of calcitonin gene-related peptide receptor (CGRP) . Ubrogepant has high affinity for CGRP receptors in human and rhesus monkeys, and can effectively block the cAMP response stimulated by α-CGRP. Ubrogepant can be used in the study of acute migraine[1][2].

Product Specifications

CAS Number

[1374248-77-7]

Product Name Alternative

MK-1602

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

CGRP Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Ubrogepant.html

Purity

99.90

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

O=C(C1=CN=C2C(C[C@@]3(C4=CC=CN=C4NC3=O)C2)=C1)N[C@@H]5C(N(CC(F)(F)F)[C@H](C)[C@H](C6=CC=CC=C6)C5)=O

Molecular Formula

C29H26F3N5O3

Molecular Weight

549.54

Precautions

H302, H315, H319, H335

References & Citations

[1]Li CC, et al. Population PK Analyses of Ubrogepant (MK-1602), a CGRP Receptor Antagonist: Enriching In-Clinic Plasma PK Sampling With Outpatient Dried Blood Spot Sampling. J Clin Pharmacol. 2017 Nov 14. doi: 10.1002/jcph.1021.|[2]Moore E, et al. Characterization of Ubrogepant: A Potent and Selective Antagonist of the Human Calcitonin Gene‒Related Peptide Receptor. J Pharmacol Exp Ther. 2020 Jan 28:jpet.119.261065.